NHMRC Postdoctoral Research Officer
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Barratt is an early career researcher in the Clinical Pharmacogenomics and Drug Metabolism and Pharmacokinetics Laboratories of the Discipline of Pharmacology. He is also a member of the University of Adelaide Centre for Personalised Cancer Medicine.
He is currently a NHMRC Postdoctoral Research Officer investigating personalised medicines for Aboriginal people with Prof Andrew Somogyi. He also has an extensive research background in the clinical pharmacogenomics of opioid analgesics, and the genetics of pain more generally. In addition, he leads research integrating clinical and experimental pharmacokinetics, pharmacogenomics and drug resistance markers, for the personalised dosing of tyrosine kinase inhibitors against cancer.
My research is primarily in the area called "pharmacogenetics" or more commonly now, "pharmacogenomics"; determining how our genetics influence our individual responses to drugs, and how this can be used to better personalise treatments for improved safety and efficacy.
Together with Prof Andrew Somogyi, one of our current major projects titled "Personalised Medicines for Aboriginal People" aims to identify common drug-related genetic variants in Aboriginal and non-Aboriginal Australians, to compare and contrast this variability, and ultimately guide recommendations for personalised prescribing in Aboriginal people.
In addition, I investigate the clinical pharmacogenomics of opioid analgesic pharmacokinetics, and the neuronal and innate immune genetics of pain and analgesia. Specifically, my involvement in large international collaborative projects is generating novel insights into how innate immune genetic factors can underlie patient variability in acute and persistent postoperative pain and analgesia, as well as pain, cognitive dysfunction and other adverse symptoms in cancer patients.
I also conduct research integrating clinical and experimental pharmacokinetics, pharmacogenetics and mechanisms of drug resistance, for the personalised dosing of tyrosine kinase inhibitors (TKI) used to treat cancer, including the largest studies to date of the genetics of imatinib disposition in leukaemia patients. I am currently also collaborating on projects examining the pharmacogenetics of immunosuppressants, and pharmacogenetic variability in Papua New Guinea related to treatments for infectious diseases.
Year Citation 2016 Coller, J. K., Barratt, D. T., & Somogyi, A. A. (2016). Clinically significant interactions with anti-addiction agents. In M. W. Jann, S. R. Penzak, & L. J. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger.
Year Citation 2016 Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia.
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 Co-Supervisor Infectious diseases pharmacokinetics Doctor of Philosophy Doctorate Full Time Ms Natalia Bordin Andriguetti 2018 Co-Supervisor Pharmacogenomics in Indigenous Populations Doctor of Philosophy Doctorate Full Time Miss Helena Katherina Van Schalkwyk
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2016 - 2019 Co-Supervisor Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes Doctor of Philosophy Doctorate Full Time Ms Rong Hu 2014 - 2015 Co-Supervisor Impact of CYP2C8 Single Nucleotide Polymorphisms on In-vitro Metabolism of Imatinib to N-desmethyl Imatinib Master of Philosophy (Medical Science) Master Full Time Mr Muhammad Suleman Khan
Date Role Committee Institution Country 2016 - ongoing Member Adelaide Medical School Health Safety and Welfare Committee — — 2013 - ongoing Member ASCEPT Scientific Advisory Committee — — 2013 - ongoing Vice-Chair ASCEPT Pharmacogenomics Special Interest Group — —
Date Role Membership Country 2005 - ongoing Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists —
Connect With Me